ImetelChat

There was an interesting article in Bloodjournal.org back in Feb on treating MF patients failing Jak inhibitor tx. Very encouraging for imet prospects. Jak patient dropout and adverse effects noted makes the clinical hold on imet way back when even more fishy. Have no proof, but I would bet someone at Celgene or Incy had some influence on the fda that has delayed imet development in a criminal, unethical way. Would love to see some investigation into that!

dongonenuts, Here's the reference, its an open article and is readily accessible, Dr T is one of the authors. I think we have discussed it before and ideally I would like to provide access via the library but as you know that's a work in progress! Regards, bp

How I treat myelofibrosis after failure of JAK inhibitors
Animesh Pardanani and Ayalew Tefferi
Blood 2018 132:492-500; doi: https://doi.org/10.1182/blood-2018-02-785923